Themis Medicare Ltd.

THEMISMED

₹148.44

0.11% (0.17)

Market Cap

₹1,364 Cr.

P/E

29.56

About

Themis Medicare Ltd. is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives. T… Read more

Themis Medicare Ltd. is a research-based pharmaceutical company specializing in manufacture of… Read more

Low

142

52W Range

High

317

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Balance sheet
Net Block	117	124	126	123	116	133	144	162	168	174
Shareholders Funds	74.03	152	169	158	183	219	287	339	378	412
Profit & Loss
Operating Profit	38.16	32.37	24.53	2.28	35.66	49.49	95.64	67.45	51.51	—
Net Sales	232	217	210	184	202	231	395	354	382	—
Cash flow
Cash from Operating Activity	25.76	-1.51	7.86	10.92	0.33	56.98	34.39	16.09	22.09	38.37
Net Capex (est)	7.96	5.34	3.13	5.48	5.77	17.99	19.30	28.71	18.39	19.00
Ratios
ROCE (%)	20.34	17.63	11.74	-1.89	16.19	18.35	29.13	18.26	10.69	—
ROE (%)	21.99	10.47	6.68	-6.79	13.54	16.34	25.35	16.76	11.52	—

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a good pace
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Capex vs ROCE

Roce of the company has decreased even without significant capex
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Working Capital

Company has significant working capital which is dragging its roce and roe
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Verticals

Operational Metrics

R&D as a % of Total Sales (%)

Themis Medicare Ltd.

R&D as a % of Total Sales (%)
Source

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Themis Medicare	147.21	29.65	1,368	67.15	13.69	10.69	11.52
Hester Biosciences	1,667.35	40.72	1,268	53.73	-5.62	8.47	6.47
Shree Ganesh Remed.	722.65	32.19	935	72.8	-3.29	25.46	23.02
IOL Chem & Pharma	62.3	19.23	1,870	52.62	0.56	11.74	8.34
Kopran	188.5	19.01	903	44.46	4.61	14.51	10.37
SMS Pharmaceuticals	216.26	29.32	1,938	64.67	7.35	12.77	9.29
NGL Fine-Chem	1,129	21.51	702	72.74	1.3	20.91	15.67
Bajaj Healthcare	660.9	0.00	2,120	59.19	13.1	16.82	-30.1

Corporate Actions

Consolidated DividendSplit

DATE

DETAILS

2024, Jul 12

Dividend Dividend of Rs.0.5 per share

2023, Oct 10

Split 1 shares held will now become 10. New number of shares should be credited and listed within 1 day after the ex-date.

2023, Sep 01

Dividend Dividend of Rs.5 per share

2022, Sep 08

Dividend Dividend of Rs.5 per share

2021, Sep 08

Dividend Dividend of Rs.4.3 per share

FAQs on Themis Medicare Ltd. Business

What does Themis Medicare do?

Themis Medicare Ltd. is a research-based pharmaceutical company focusing on Pain Management, Critical Care, and Anti-Infectives. It develops differentiated products for patient benefit.

Who are the competitors of Themis Medicare?

Themis Medicare major competitors are Hester Biosciences, Shree Ganesh Remed., IOL Chem & Pharma, Kopran, SMS Pharmaceuticals, NGL Fine-Chem, Bajaj Healthcare.
Market Cap of Themis Medicare is ₹1,368 Crs.
While the median market cap of its peers are ₹1,268 Crs.

Is Themis Medicare financially stable compared to its competitors?

Themis Medicare seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release				Sep	Sep Dec
Investor Presentation		Mar Jun Sep Dec	Mar Jun Sep Dec	Sep Dec
Conference Call			Mar Sep	Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Themis Medicare Ltd.

Interview With Dr Sachin Patel, CEO, Themis Medicare and Gujarat Themis Biosyn - Sensei Kujaku

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Themis Medicare Ltd.